ACADIA Pharmaceuticals (ACAD) Competitors

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Is ACAD or GMAB more profitable?

Genmab A/S has a net margin of 37.53% compared to ACADIA Pharmaceuticals' net margin of 21.80%. Genmab A/S's return on equity of 21.03% beat ACADIA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	21.80%	14.69%	9.41%
Genmab A/S	37.53%	21.03%	16.98%

Do insiders & institutionals believe in ACAD or GMAB?

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 26.5% of ACADIA Pharmaceuticals shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Which has better valuation and earnings, ACAD or GMAB?

Genmab A/S has higher revenue and earnings than ACADIA Pharmaceuticals. Genmab A/S is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$957.80M	4.39	$226.45M	$1.33	18.74
Genmab A/S	$3.12B	5.03	$1.14B	$1.99	12.29

Which has more risk and volatility, ACAD or GMAB?

ACADIA Pharmaceuticals has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500.

Do analysts recommend ACAD or GMAB?

ACADIA Pharmaceuticals currently has a consensus price target of $28.88, indicating a potential upside of 15.84%. Genmab A/S has a consensus price target of $37.60, indicating a potential upside of 53.69%. Given Genmab A/S's stronger consensus rating and higher probable upside, analysts clearly believe Genmab A/S is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.61
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

Does the media favor ACAD or GMAB?

In the previous week, ACADIA Pharmaceuticals had 3 more articles in the media than Genmab A/S. MarketBeat recorded 13 mentions for ACADIA Pharmaceuticals and 10 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.10 beat ACADIA Pharmaceuticals' score of 0.87 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Genmab A/S beats ACADIA Pharmaceuticals on 11 of the 16 factors compared between the two stocks.